BACKGROUND/AIMS: This study investigated the role of JAK/STAT, an important pathway for cytokine signal transduction, in the progression of chronic glomerular diseases. METHODS: BALB/c mice received a single intravenous injection of adriamycin (10 mg/kg) were sacrificed 2, 4 and 6 weeks later. In the second study, treatment with the selective JAK2 inhibitor AG490 (15 mg/kg, q.d., i.p.) or vehicle was started 5 days after adriamycin injection. Functional and pathologic markers, inflammatory infiltration, expression of pro-inflammatory cytokines and phosphorylation of JAK2/STATs were assessed. RESULTS: JAK/STAT signaling was activated in adriamycin nephropathy. Phosphorylation of JAK2, STAT1 and STAT3 was significantly inhibited by AG490 (p <0.01). Compared to the vehicle-treated controls, AG490 treatment did not reduce proteinuria 2 weeks after induction of the disease, but resulted in significant decrease in proteinuria and serum creatinine at week 6 (p <0.05). Glomerulosclerosis, tubulointerstitial lesions and renal alpha-SMA expression were also significantly suppressed by AG490 treatment at week 6 (p < 0.01). In addition, AG490 inhibited the expression of MCP-1 mRNA, accompanied by reduced interstitial infiltration of macrophages and T cells (p <0.05). CONCLUSIONS: This study suggests that activation of JAK/STAT signaling is involved in the progression of glomerular diseases with proteinuric state. (c) 2007 S. Karger AG, Basel.
BACKGROUND/AIMS: This study investigated the role of JAK/STAT, an important pathway for cytokine signal transduction, in the progression of chronic glomerular diseases. METHODS: BALB/c mice received a single intravenous injection of adriamycin (10 mg/kg) were sacrificed 2, 4 and 6 weeks later. In the second study, treatment with the selective JAK2 inhibitor AG490 (15 mg/kg, q.d., i.p.) or vehicle was started 5 days after adriamycin injection. Functional and pathologic markers, inflammatory infiltration, expression of pro-inflammatory cytokines and phosphorylation of JAK2/STATs were assessed. RESULTS: JAK/STAT signaling was activated in adriamycinnephropathy. Phosphorylation of JAK2, STAT1 and STAT3 was significantly inhibited by AG490 (p <0.01). Compared to the vehicle-treated controls, AG490 treatment did not reduce proteinuria 2 weeks after induction of the disease, but resulted in significant decrease in proteinuria and serum creatinine at week 6 (p <0.05). Glomerulosclerosis, tubulointerstitial lesions and renal alpha-SMA expression were also significantly suppressed by AG490 treatment at week 6 (p < 0.01). In addition, AG490 inhibited the expression of MCP-1 mRNA, accompanied by reduced interstitial infiltration of macrophages and T cells (p <0.05). CONCLUSIONS: This study suggests that activation of JAK/STAT signaling is involved in the progression of glomerular diseases with proteinuric state. (c) 2007 S. Karger AG, Basel.
Authors: Corina M Borza; Yan Su; Xiwu Chen; Ling Yu; Stacey Mont; Sergei Chetyrkin; Paul Voziyan; Billy G Hudson; Paul C Billings; Hyunil Jo; Joel S Bennett; William F Degrado; Beate Eckes; Roy Zent; Ambra Pozzi Journal: J Am Soc Nephrol Date: 2012-03-22 Impact factor: 10.121
Authors: Patricia M García-García; María A Getino-Melián; Virginia Domínguez-Pimentel; Juan F Navarro-González Journal: World J Diabetes Date: 2014-08-15
Authors: Xiaobei Feng; Ting-Chi Lu; Peter Y Chuang; Wei Fang; Krishna Ratnam; Huabao Xiong; Xinshou Ouyang; Yuhong Shen; David E Levy; Deborah Hyink; Mary Klotman; Vivette D'Agati; Ravi Iyengar; Paul E Klotman; John C He Journal: J Am Soc Nephrol Date: 2009-07-16 Impact factor: 10.121
Authors: Ting-Chi Lu; Zhao-Hui Wang; Xiaobei Feng; Peter Y Chuang; Wei Fang; Yuhong Shen; David E Levy; Huabao Xiong; Nan Chen; John Cijiang He Journal: Kidney Int Date: 2009-04-08 Impact factor: 10.612
Authors: Victoria L M Herrera; Pia Bagamasbad; Tamara Didishvili; Julius L Decano; Nelson Ruiz-Opazo Journal: Physiol Genomics Date: 2008-04-15 Impact factor: 3.107